201.29 0.00 (0.00%)
After hours: 4:48PM EDT
|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||200.33 - 201.66|
|52 Week Range||155.68 - 206.66|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||18.98|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||2.00 (0.99%)|
|1y Target Est||205.93|
For a growing number of companies, offering employees student loan assistance is a way to differentiate in a tight labor market.
Aetna today announced that third-quarter 2018 results will be made public on Tuesday, October 30, at 6:30 a.m. ET. Given the pending transaction with CVS Health, Aetna will not host a conference call in conjunction with its earnings release.
In late October 2017, U.S. drugstore operator CVS Health Corp (NYSE:CVS) announced intentions to acquire U.S. health insurer Aetna Inc (NYSE:AET) in a $69 billion dollar deal that promised to permanently alter the healthcare industry. DOJ approval means that it is time to take profits on Aetna stock. Aetna stock initially jumped to nearly $200 by January 2018.
On October 10, the US Department of Justice gave preliminary approval to the $69 billion deal between CVS Health (CVS) and Aetna (AET). CVS Health, America’s largest pharmacy chain, proposed the acquisition of Aetna, the country’s third-largest insurance company, in December 2017 for $207 per share. The clearance from the DOJ is among the most important milestones towards completing the deal.
Joan Hayner is paying attention to the new models emerging in the health care industry as she looks at how Community Care Physicians delivers its services.
Justice Department antitrust enforcers cleared CVS Health Corp.’s acquisition of Aetna Inc. after the companies took steps to ease regulators’ concerns, moving the nearly $70 billion deal a major step closer. The Wall Street Journal had earlier reported that federal antitrust officials were preparing to give the deal a green light, but the overlap in the two companies’ Medicare drug businesses had to be addressed. Aetna in late September announced the planned divestiture of its Medicare drug business to WellCare Health Plans Inc.
WASHINGTON/NEW YORK (Reuters) - Pharmacy chain CVS Health Corp won U.S. antitrust approval for its $69 billion acquisition of health insurer Aetna Inc, the Justice Department said on Wednesday, paving the way for a combination with potential to cut U.S. healthcare costs for consumers. The companies have said they will save administrative and patient care costs when they combine, in part by steering Aetna customers to walk-in clinics in CVS stores for less expensive medical services. It is the second large recent healthcare deal to win U.S. Justice Department approval.
When UnitedHealth Group (UNH) releases its third quarter of fiscal 2018 earnings results on October 16, analysts expect it to register adjusted EPS of ~$3.29, a ~23.8% growth YoY (year-over-year). In the second quarter, it reported adjusted EPS of ~$3.14, representing a ~27.6% YoY growth.
On October 16, UnitedHealth Group (UNH) is expected to announce its third quarter of fiscal 2018 earnings. Its sales are expected to grow 12% YoY (year-over-year) to $56.3 billion. In the second quarter of fiscal 2018, it had sales of $56.1 billion, representing ~12.1% YoY growth, which was in line with analysts’ estimates.
Or at the very least, it has no problem when it comes to these types of deals and health care. CVS Health Corp.’s $69 billion purchase of insurer Aetna Inc. — the fifth-largest health-care deal ever — got conditional approval from the Department of Justice on Wednesday. The DOJ only requires the already in-progress divestiture of Aetna’s Medicare drug plans in order to approve the deal.
UnitedHealth Group (UNH) is the leading health insurance company in the United States. This managed healthcare company is focused on establishing itself as a diversified healthcare business and has been recently undertaking a number of strategic acquisitions aimed at that goal.
WASHINGTON/NEW YORK (Reuters) - Pharmacy chain CVS Health Corp (CVS.N) won U.S. antitrust approval for its $69 billion acquisition of health insurer Aetna Inc (AET.N), the Justice Department said on Wednesday, paving the way for a combination with potential to cut U.S. healthcare costs for consumers. The companies have said they will save administrative and patient care costs when they combine, in part by steering Aetna customers to walk-in clinics in CVS stores for less expensive medical services. It is the second large recent healthcare deal to win U.S. Justice Department approval.
CVS Health Corporation (NYSE: CVS ) is one step closer to acquiring Aetna Inc. (NYSE: AET ) after the U.S. Department of Justice preliminary approved the $69 billion merger. What Happened CVS proposed ...
have received conditional approval from the Department of Justice on their $69 billion merger. The DOJ said Wednesday, Oct. 10, it is requiring the companies to divest Aetna's Medicare Part D prescription drug business in order to go through with the transaction. The deal announced by Aetna on Sept. 27 to sell its Medicare Part D prescription drug plan business to WellCare Health Plans Inc. WCG will fully resolve the DOJ's concerns on competition, according to the news release.
The proposed $69 billion merger between CVS Health and Aetna is getting a greenlight from the Department of Justice, with some conditions. The Justice Department on Wednesday approved the deal on the condition that Aetna moves ahead with its plan to sell its Medicare Part D prescription drug plan business, resolving some anti-monopoly issues. Aetna announced last month it'd sell the business for an undisclosed amount.
WOONSOCKET, R.I., Oct. 10, 2018 /PRNewswire/ -- CVS Health (CVS) today announced that it has entered into an agreement with the U.S. Department of Justice (DOJ) that allows it to proceed with its proposed acquisition of Aetna (AET). DOJ clearance is a key milestone toward finalizing the transaction, which is also subject to state regulatory approvals, many of which have been granted. CVS Health's acquisition of Aetna remains on track to close in the early part of Q4 2018.
The Justice Department said Wednesday that CVS Health and Aetna will have to divest Aetna's Medicare Part D prescription drug plan business to proceed with its merger. The proposed divestiture to WellCare Health Plans, Inc. would fully resolve the Justice Department's competition concerns, the agency said.
CVS CEO Larry Merlo outlined his vision for the combined company earlier this month — a new data-driven health-care model that's more personal, convenient and tailored to individual patients than ever before.
The Justice Department is expected to approve the deal as early as Wednesday. The companies cleared their path to approval when Aetna announced Sept. 27 that it reached an agreement to sell its Medicare Part D drug plan business to WellCare Health Plans. Shares of CVS Health CVS and Aetna AET edged higher Wednesday as the companies come closer to winning regulatory approval for their $69 billion merger.
Yahoo Finance’s Seana Smith on the stocks making headlines in midday trading Wednesday.